Immunobiology of a Spontaneous Murine B Cell Leukemia (BCL<sub>1</sub>)

Strober, Samuel; Gronowicz, Eva; Knapp, Michael; Slavin, Shimon; Vitetta, Ellen S.; Warnke, Roger A.; Kotzin, Brian L.; Schröder, Jim

doi:10.1111/j.1600-065x.1979.tb00303.x

Cited by 55 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: In Vivo Experimentsmentioning

confidence: 99%

“…Animals were observed for signs or symptoms of tumor growth (massive splenomegaly), and time from cell injection to animal death was monitored as previously described. 22 The cause of death was determined by necropsy.To explore the capacity of the CD8 ϩ NKT cells to cause GVHD, recipient Balb/c mice were irradiated as above and transplanted with BM cells from C57BL/6 recipients with either splenocytes or expanded CD8 ϩ NKT cells from wild-type (WT) C57BL/6 or mutant strains of mice on the B6 background at the indicated dose. Typical signs and symptoms of GVHD were observed, including ruffled fur, diarrhea, hunchback appearance, weight loss, and survival.…”

mentioning

confidence: 99%

“…This tumor cell line results in massive splenomegaly and ultimately death of the recipient animals within approximately 2 months. 22 In these studies, Balb/c mice were injected with 10 3 Bcl1 cells that were allowed to grow for 1 week to simulate active disease. The mice then received lethal irradiation to attempt to develop a state of minimal residual disease similar to the clinical situation.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production

Baker

Verneris

Ito

et al. 2001

Blood

213

171

View full text Add to dashboard Cite

IntroductionT cells with natural killer (NK) cell activity have been identified in both murine and human tissues. [1][2][3][4] Murine NKT cells typically express phenotypic markers found on T cells such as CD3 and the ␣␤T-cell receptor (TCR), as well as the NK markers NK1.1 and DX5. 5 Two populations of murine NKT cells have been described. One population either does not express the co-receptors CD4 or CD8 or are CD4 ϩ . These NKT cells express the invariant V␣14-J␣281 TCR and have been found in the liver, thymus, bone marrow (BM), and spleen with approximately 0.5 to 1.5 million cells per organ. [6][7][8] Functionally, CD4 ϩ NK1.1 ϩ NKT cells produce large amounts of interleukin 4 (IL-4) on activation. 8,9 Therefore, this population of IL-4-producing NKT cells are thought to play an important role in the regulation of immune responses, especially those of the T H 2 type. 10 CD4 ϩ NKT cells are positively selected by the major histocompatibility complex (MHC) class I-like molecule CD1d and associated ␤-2 microglobulin since these cells are markedly reduced in mice deficient in these molecules. 9,[11][12][13] Recently, a second population of NKT cells has been described that expresses a variable TCR repertoire and is not dependent on CD1d for maturation and development. 14 In addition, these CD1d-independent splenic NKT cells expressed mainly CD8 or were double negative with respect to CD4 and CD8 expression. Approximately 1% to 2% of splenocytes from C57BL/6 mice are ␣␤TCR ϩ NK1.1 ϩ , and, of these cells, approximately 20% are CD8 ϩ . 14 Little is known about the function of this later population of CD8 ϩ NKT cells.T cells are readily expandable following mitogenic stimulation with monoclonal antibodies (MAbs) directed against the TCR complex. 15 The combination of anti-CD3 and IL-2 results in the expansion of murine and human T cells capable of lysing a variety of different tumor cell lines, some of which are resistant to NK cells. [16][17][18] The expanded cells also have in vivo antitumor cell activity against murine tumors 16,19 and human tumors transplanted into immunodeficient mice. 18,20 It has been demonstrated that T cells activated with anti-CD3 and IL-2 and cultured for 6 to 8 days have a decreased capacity for inducing graft-versus-host disease (GVHD). Both CD4 ϩ and CD8 ϩ cells were less likely to result in GVHD following activation with anti-CD3 and IL-2. 21 In this report we have used culture conditions that allow for the growth of large numbers of T cells that share functional and phenotypic properties with NK cells. Following activation and culture, ␣␤TCR ϩ , CD8 ϩ , and NK1.1 ϩ T cells with NK cell function are readily expandable. We characterize the phenotype, cytokine production, and in vitro and in vivo biological activity of this population of CD8 ϩ NKT cells that have antitumor activity yet limited capacity to cause GVHD. Materials and methods AnimalsBalb/c (H-2 d ), C57BL/6 (H-2 b ), B10.D2/nSnJ (H-2 d ), FVB/J (H-2 q ), and the following mice of C57BL/6 background, fas deficient, fas li...

show abstract

Section: In Vivo Experimentsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production

Baker

Verneris

Ito

et al. 2001

Blood

213

171

View full text Add to dashboard Cite

show abstract

“…BCL 1 tumor cell passage and injection BCL 1 is a B-cell leukemia/lymphoma derived from BALB/c mice expressing a tumor-specific IgM-l surface Ig. 4,10 This cell line was maintained in vivo by serial passage in wildtype BALB/c mice as described previously. [10][11][12][13][14][15][16] A dose of 5 Â 10 2 BCL 1 cells from spleen of tumor-laden BALB/c mice was injected intravenously into transplanted BALB/c hosts and non-transplanted, sublethally irradiated or nonirradiated BALB/c controls.…”

Section: Analysis Of Splenic V B Subsetsmentioning

confidence: 99%

Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation

Pillai

Teo

George

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

“…23 This cell line was maintained by serial passage in BALB/c mice as described previously. 23 BCL 1 cells (1 ϫ 10 6 ) from the spleen of BALB/c mice were injected intravenously into normal BALB/c recipients, to allow the lymphoma to grow in the recipients for 13 days before the conditioning treatment.…”

Section: Bcl 1 Tumor Cell Passage and Injectionmentioning

confidence: 99%

Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor–αβ

Lan

Zeng

Huie

et al. 2001

Blood

Self Cite

View full text Add to dashboard Cite

Immunobiology of a Spontaneous Murine B Cell Leukemia (BCL₁)

Cited by 55 publications

References 21 publications

Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production

Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production

Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation

Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor–αβ

Contact Info

Product

Resources

About

Immunobiology of a Spontaneous Murine B Cell Leukemia (BCL1)

Cited by 55 publications

References 21 publications

Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production

Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production

Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation

Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor–αβ

Contact Info

Product

Resources

About

Immunobiology of a Spontaneous Murine B Cell Leukemia (BCL₁)